FieldForce PFA System VCAS Trial Shows Promising Results Published in Circulation Months Freedom from VT VF and High Burden Reduction

Field Medical Announces Positive Six-Month Outcomes from Ventricular Tachycardia Ablation Study

Field Medical, Inc. has announced the publication of six-month outcomes from the Ventricular Catheter Ablation Study (VCAS) in the journal Circulation. This study marks the first-in-human evaluation of Field Medical’s FieldForce™ Ablation System for treating ventricular tachycardia (VT).

Key Highlights of the VCAS Study

The VCAS study focused on assessing the safety and efficacy of the FieldForce™ Ablation System in patients with ventricular tachycardia. Ventricular tachycardia is a rapid heart rhythm that can be life-threatening.

About the FieldForce™ Ablation System

The FieldForce™ Ablation System represents a novel approach to VT ablation, designed to improve the precision and effectiveness of the procedure. It is designed for:

• Enhanced accuracy in targeting VT substrates.
• Improved contact and stability during ablation.
• Real-time feedback for optimized energy delivery.

Study Outcomes

The six-month outcomes published in Circulation demonstrate promising results:

• Significant reduction in VT episodes post-ablation.
• Favorable safety profile with minimal adverse events.
• Improved quality of life for patients treated with the FieldForce™ system.

Implications for VT Treatment

These findings suggest that the FieldForce™ Ablation System could offer a valuable new option for patients suffering from ventricular tachycardia. The study provides a foundation for further research and development in the field of cardiac electrophysiology.

Future Directions

Field Medical, Inc. is committed to continuing its research efforts to refine and expand the applications of the FieldForce™ Ablation System. Ongoing studies will focus on long-term outcomes and broader patient populations.

Final Overview

The successful six-month outcomes from the VCAS study represent a significant milestone for Field Medical, Inc. and offer new hope for individuals with ventricular tachycardia. The FieldForce™ Ablation System shows potential to transform VT treatment and improve patient outcomes.